Ora | Jotup

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Retrieved on:

Friday, March 22, 2024

Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.

Key Points:

Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.
Tear Film Break-up Time showed statistically significant improvement as early as day 15 with the benefit durable for the remainder of the trial.
Burning/Stinging, and Blurred Vision improved as early as day 15 and the benefit remained durable throughout the trial.
Significant improvements were observed across multiple symptoms as measured in a daily symptom diary including pain, burning/stinging, eye dryness and itching within the first two weeks of treatment.

SDC Optimizes Focus on Tech-Enabled Biometric Services

Retrieved on:

Tuesday, March 5, 2024

Technology, Research, Other Technology, Health Technology, Biotechnology, Health, Pharmaceutical, Optical, Science, Ophthalmology, Ora, SDC, Biostatistics, IRT, Clinical trial, Statistics, Data management, EDC, Partnership

Statistics & Data Corporation (SDC), a global leader in life sciences biometrics services and technology solutions, announces a strategic decision to enhance focus and efficiency by transitioning its ophthalmic biometric division to its partner Ora, Inc.

Key Points:

Statistics & Data Corporation (SDC), a global leader in life sciences biometrics services and technology solutions, announces a strategic decision to enhance focus and efficiency by transitioning its ophthalmic biometric division to its partner Ora, Inc.
During this time, SDC has developed a reputation as an industry leader in providing biometrics services and the deployment of innovative/integrated technologies across the industry.
Dr. Richard Abelson, CEO of SDC commented, "The transition of our ophthalmic biometric division signifies our unwavering dedication to excellence and innovation in clinical research services and technology solutions.
This strategic shift allows SDC to better leverage our core strengths and deliver greater value to our clients and clinical partnerships."

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease

Retrieved on:

Monday, January 8, 2024

Patient, DED, BID, Plasma protein binding, Dry, FDA, Ophthalmology, Medical director, Lubrication, Human, Ora, Telecanthus, B cell, Safety, Conjunctiva, Pharmaceutical industry

This first-in-human trial of OK-101 established a clear and informed path for further development in Phase 3 registration trials.

Key Points:

This first-in-human trial of OK-101 established a clear and informed path for further development in Phase 3 registration trials.
The double-masked, randomized, placebo-controlled Phase 2 trial was conducted at six sites in the U.S. and enrolled 240 subjects with DED dosed twice-daily (BID).
OK-101 First-In-Human trial establishes a clear clinical path for further clinical development in a Phase 3 study design using FDA recognized endpoints per the Dry Eye: Developing Drugs for Treatment Guidance for Industry.
A statistically significant improvement in blurred vision was also achieved at Day 29 (p = 0.01).

mea platform ora Continues to Lead the Market for Data Ingestion Across the Global Insurance Industry

Retrieved on:

Thursday, December 14, 2023

Growth, LLM, Broker, Ora, AI, Katok Mga Misis, GPT, Risk management, Medical device, Insurance

LONDON, Dec. 14, 2023 /PRNewswire/ -- The fastest Insurance loss ratio and book growth improvements are seen through utilising Insurance expert pre-trained AI models and advanced AI techniques for data ingestion across Insurance value chain.

Key Points:

LONDON, Dec. 14, 2023 /PRNewswire/ -- The fastest Insurance loss ratio and book growth improvements are seen through utilising Insurance expert pre-trained AI models and advanced AI techniques for data ingestion across Insurance value chain.
mea's Ora – proprietary pre-trained, Gen-AI based and secure AI - continues to lead the market for data ingestion across the global Insurance industry.
mea has already achieved deployments in over 20 countries and ingests data from millions of Insurance risks annually.
The mea team have a long background as Insurance practitioners and understand the need for security and speed of deployment.

FONTAINEBLEAU LAS VEGAS UNVEILS DAY ONE LUXURY RETAIL PARTNERS FEATURING GLOBALLY ACCLAIMED BRANDS AND FONTAINEBLEAU ORIGINAL CONCEPTS

Retrieved on:

Monday, December 11, 2023

LAS VEGAS, Dec. 11, 2023 /PRNewswire/ -- Fontainebleau Las Vegas, the luxury resort and casino brought to life by Fontainebleau Development, is unveiling the day-one partners of its visionary luxury retail experience – eight distinct concepts seamlessly integrated within 90,000 square feet across two levels, with additional concepts to debut throughout 2024. Inspired by the Fontainebleau legacy of personalized, one-of-a-kind experiences and offerings, the collection features multiple globally acclaimed designers, and notable brands such as Chrome Hearts, Missoni and Giuseppe Zanotti, alongside numerous Fontainebleau Development original concepts.

Key Points:

This way, every interaction between guests and our retail partners becomes part of their Fontainebleau Las Vegas memories.
Timeless icons, influential fashion brands, and original concepts form the foundation of the Fontainebleau Las Vegas retail experience.
Each Chrome Hearts product is handmade at the brand's factory in Hollywood and designed specifically for the Fontainebleau Las Vegas guest.
Now, the Italian luxury footwear and fashion designer opens his exclusive Las Vegas flagship store on the Bleau Galerie level of Fontainebleau Las Vegas.

Navigating Industry Needs for Retina Therapy Clinical Research Success, Upcoming Webinar Hosted by Xtalks

Retrieved on:

Monday, November 27, 2023

EST, Ora, Patient, Neuroprotection, Diabetic retinopathy, Macular degeneration, Pharmaceutical industry

TORONTO, Nov. 27, 2023 /PRNewswire-PRWeb/ -- In this groundbreaking webinar, discover the latest in retina therapy programs and clinical research to enhance success in ophthalmic trials with insights from industry experts. With over 250 individual therapies in development to address these challenging-to-treat conditions including inherited retina diseases, diabetic retinopathy and macular degeneration, the innovation within this space is likely unsurpassed by any other. Excitingly, many of these include novel mechanisms of action or gene therapies that show potential for different therapeutic impacts from current therapies on the market, such as treating conditions where there are no therapies with approved indications or targeting earlier-stage disease interventions.

Key Points:

In this free webinar, hear about lessons learned and important considerations for novel retina therapy programs.
Attendees will get insights from experts about the latest published research and regulatory agency reviews of clinical designs.
TORONTO, Nov. 27, 2023 /PRNewswire-PRWeb/ -- In this groundbreaking webinar, discover the latest in retina therapy programs and clinical research to enhance success in ophthalmic trials with insights from industry experts.
Join this webinar to gain insights into retina therapy programs in clinical research from industry experts to maximize success in the challenging field of ophthalmic clinical trials.

Endpoints for Neuroprotection in Glaucoma Trials, Upcoming Webinar Hosted by Xtalks

Retrieved on:

Wednesday, November 22, 2023

R, Eye, HIV disease progression rates, IOP, Ora, Intraocular pressure, Research, Patient, Neuroprotection, Paratriathlon, FDA, Glaucoma, Pharmaceutical industry

TORONTO, Nov. 22, 2023 /PRNewswire-PRWeb/ -- Join us for a cutting-edge webinar delving into innovative clinical approaches and endpoints for new glaucoma treatments. Today, intraocular pressure (IOP) lowering therapies are currently the only proven neuroprotective therapies for glaucoma. While IOP therapies and devices are highly prevalent in use, unfortunately even with these treatments up to one in four patients still experience blindness in at least one eye. With disease progression still often significant despite the application of these therapies, this is an opportunity for new therapeutic entries. As companies explore new therapies to provide neuroprotection (preserving neuronal integrity) or even neuroenhancement (improving neuronal function), finding the right clinical approaches and endpoints to prove efficacy is paramount.

Key Points:

In this free webinar, learn designs and endpoints for new glaucoma therapies that help better measure therapeutic impact and even demonstrate intraocular pressure (IOP)-independent neuroprotection.
The featured speaker will discuss the latest research shaping the future of glaucoma clinical trials.
TORONTO, Nov. 22, 2023 /PRNewswire-PRWeb/ -- Join us for a cutting-edge webinar delving into innovative clinical approaches and endpoints for new glaucoma treatments.
This webinar, featuring leading glaucoma expert and Ora Chief Medical Officer, Dr. Gustavo De Moraes, highlights ground-breaking designs and endpoints for new glaucoma therapies that help better measure therapeutic impact and even demonstrate IOP-independent neuroprotection.

Rita Ora x Primark: From loyal customer to global brand partner - Primark joins forces with Rita Ora for new fashion collaboration

Retrieved on:

Tuesday, September 12, 2023

Partnership, International, Friends, Hoodie, You and I, Innovation, Golborne Road, History, Trellick Tower, Collection, Child, Love, Ora, Shoe, Fashion design, Primark

Following a weekend of speculation sparked by Primark's window black-out across its entire store estate, Primark today unveils Rita Ora x Primark: a versatile new fashion line almost two years in the making.

Key Points:

Following a weekend of speculation sparked by Primark's window black-out across its entire store estate, Primark today unveils Rita Ora x Primark: a versatile new fashion line almost two years in the making.
The collection was closely co-designed by Primark and Rita alongside emerging London-based designer Jawara Alleyne, and styled by Rita's stylist Pippa Atkinson.
The instant chemistry between both parties was undeniable, and today, following months of collaboration, I'm so proud to be revealing Rita Ora x Primark.
The first Rita Ora x Primark collection will be available in all of Primark's stores across its 16 markets from Tuesday 19 September.

OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)

Retrieved on:

Wednesday, August 30, 2023

DED, CSO, Tears, Inflammation, Pain, Patient, Ora, Safety, Pharmaceutical industry

"We are very pleased at the rapid pace of enrollment we are seeing in our ongoing Phase 2 trial of our flagship drug OK-101 to treat patients with DED.

Key Points:

"We are very pleased at the rapid pace of enrollment we are seeing in our ongoing Phase 2 trial of our flagship drug OK-101 to treat patients with DED.
This trial began in May of this year, with the first patient being randomized in June into one of the three cohorts.
Having enrolled 90% of the patients in this trial is an important milestone for OKYO Pharma,” said Gary S. Jacob, Ph.D., CEO of OKYO Pharma.
Dry eye disease is a common condition that occurs when one’s tears are unable to adequately lubricate the eyes.

Nexgrill creates guide to its most giftable products ahead of the holiday season

Retrieved on:

Wednesday, August 30, 2023

CHINO, Calif., Aug. 30, 2023 /PRNewswire-PRWeb/ -- As the autumn season approaches, so does the start of holiday gift planning. To help consumers get ahead of their holiday shopping, Nexgrill has introduced a new guide to its "giftable" outdoor appliances. Products include the brand's new Ora Pizza Oven, Daytona Griddles in compact sizes, the Fortress 1-burner Portable Gas Grill, and the Neevo Smart Grill with Air Fryer.

Key Points:

To help consumers get ahead of their holiday shopping, Nexgrill has introduced a new guide to its "giftable" outdoor appliances.
"Our Nexgrill gift guide presents thoughtfully curated products meant to create unforgettable experiences and culinary creativity," said Ramsay Hawfield, Vice President of Marketing.
Dive into the Nexgrill Holiday Gift Guide:
Share the joy of crafting personal pizzas with family and friends at this year's holiday gatherings with the Ora Pizza Oven .
For more information about Nexgrill and its entire catalog of grills, smart grills, griddles and smokers, please visit https://nexgrill.com/ .